Isis Pharmaceuticals Gets $3.5M From Biogen Idec

Carlsbad-based biopharmaceuticals developer Isis Pharmaceuticals reported Thursday that it has received $3.5M in a milestone payment, from Biogen Idec. The company said the payment was received as part of a Phase 2 study milestone of a treatment for infants with spinal muscular atrophy (SMA). Isis is collaborating with Biogen Idec to develop and potentially commercialize the compound. The two had inked a deal in January of 2012 for the development and licensing of the drug.